Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Схожие документы

• Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  по: Yiu, Zenas Z.N., et al.
  Опубликовано: (2018)
• Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  по: Iskandar, Ireny Y.K., et al.
  Опубликовано: (2018)
• Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
  по: Yiu, Z.Z.N., et al.
  Опубликовано: (2019)
• Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
  по: Mahil, S.K., et al.
  Опубликовано: (2019)
• Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
  по: Rungapiromnan, W., et al.
  Опубликовано: (2017)